Use of mitomycin C in the treatment of conjunctival primary acquired melanosis with atypia
J. Frucht-Pery and J. Pe'er
Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel.
A patient who had primary acquired melanosis with marked atypia shown on
histological studies received topical 0.02% mitomycin C for 2 weeks and
0.04% mitomycin C for an additional 2 weeks. Conjunctival biopsy specimens
were obtained to evaluate the efficacy of the treatment. After the first
course of mitomycin C administration, some decrease of conjunctival
pigmentation was seen, and histological studies disclosed a lower degree of
atypia. After the second application of mitomycin C, the pigmentation
disappeared except for one small spot that contained only a few typical
melanocytes on histological study. The clinical findings did not change
during 7 months of follow-up. No adverse reactions to topical mitomycin C
occurred except for mild conjunctival hyperemia at the end of the courses
of treatment. Administration of topical mitomycin C may be an effective
medical treatment for primary acquired melanosis with atypia.
